TGA Response: Prohibited Ingredients in E-Cigarettes

Regulations by 2FIRSTS.ai
Jun.21.2023
TGA Response: Prohibited Ingredients in E-Cigarettes
Australian authority fines and issues infringement notices to e-cigarette importers for containing banned ingredients.

The Therapeutic Goods Administration (TGA) in Australia had issued 38 infringement notices and imposed fines totalling AUD 588,840 against four importers of e-cigarettes for violating regulations.

 

The TGA laboratory has found prohibited substances in disposable e-cigarette samples from the brands IGET, GUNNPOD, and HQD, as per the therapeutic goods order for nicotine e-cigarette products (TGO 110) for 2021.

 

In response to the incident, 2FIRSTS promptly conducted an email interview with TGA. On June 21st, TGA Spokesperson replied to 2FIRSTS via email. TGA stated in their response that the disposable e-cigarette products IGET Bar, IGET Legend, GUNNPOD, and HQD were found to contain three prohibited ingredients: benzaldehyde, cinnamaldehyde, and ethylene glycol. According to a search on the TGA official website, (Standard for Nicotine Vaping Products) (TGO 110) Order 2021 specifies the three ingredients are prohibited in e-cigarette products.

 

The following response is from a spokesperson for the Australian Therapeutic Goods Administration.

 

Please attribute the following response to a spokesperson the Therapeutic Goods Administration.

 

1.Is it possible to announce the prohibited ingredients contained in IGET, GUNPOD and HQD branded vapes referenced in the media release?

 

Testing conducted by Therapeutic Goods Administration (TGA) Laboratories identified the IGET Bar and IGET Legend disposable pod devices contained benzaldehyde, cinnamaldehyde and ethylene glycol; Gunnpod disposable pod devices were found to contain benzaldehyde and ethylene glycol; and HQD disposable pod devices were found to contain benzaldehyde, cinnamaldehyde and ethylene glycol.

 

2.Will there be other punishments for the enterprises named, such as arrests? Will the enterprises that produce and manufacture these products also be punished?

 

Infringement notices are one of the compliance tools the TGA can use when we believe that a requirement of the Therapeutic Goods Act 1989 has been breached. If an entity does not pay the infringement notice, the TGA may take further action such as formal court action.

 

The Therapeutic Goods Act 1989 regulates the import, export, supply, manufacture and supply of therapeutic goods within Australia. As the products subject to the infringement notices are manufactured outside of Australia, the manufacturers are not subject to Australian laws.

 

3.Will TGA strengthen supervision in the future?

 

On 2 May 2023, the Minister for Health and Aged Care announced that the Australian Government is taking strong action to combat the supply of unlawful vaping products. The TGA is working closely with state and territory governments and the Australian Border Force to introduce a comprehensive range of reforms, including:

  • stopping the import of non-prescription vapes;
  • increasing the minimum quality standards for vapes including by restricting flavours, colours, and other ingredients;
  • requiring pharmaceutical-like packaging;
  • reducing nicotine concentrations and volumes;
  • banning all single use disposable vapes; and
  • ending vape sales in convenience stores and other retail settings.

 

Note: The previously mentioned "GUNPOD" should be corrected to "GUNNPOD," as stated by TGA in their email reply.

 

Reference(s):

 

Three TSG stores based in Sydney and Jaradat and Sabbagh Group Pty Ltd have been issued with infringement notices totalling $588,840.


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27
DATA|UK Retail Research Group IGD Says Convenience Tobacco and Vape Sales Fell 10.6%, With 15.4% Market Share Versus Alcohol's 15.1%; Top Rank at Risk in 2027
DATA|UK Retail Research Group IGD Says Convenience Tobacco and Vape Sales Fell 10.6%, With 15.4% Market Share Versus Alcohol's 15.1%; Top Rank at Risk in 2027
Combined tobacco and vaping sales in UK convenience stores fell 10.6% year over year in the first half of 2026, making the category a major drag on channel performance, according to retail research organization IGD. Total convenience sales declined 1.2%, while sales excluding tobacco and vaping increased 0.7%. IGD's 2026 category-share figures show tobacco and vaping accounting for 15.4% of convenience sales, compared with 15.1% for alcohol. The organization forecasts alcohol could overtake tobacco and vaping as the largest category by sales value as early as 2027 if current trends continue. IGD expects the convenience market to increase from £48.6 billion in 2026 to £54.9 billion in 2031, a 2.5% compound annual growth rate, or 3.4% excluding tobacco and vaping.
DATA
Nov.11
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands (TPB) reported third-quarter 2026 Modern Oral net sales of $74.4 million on November 9, up 102.9% year over year and representing 49.2% of consolidated net sales. Total company net sales rose 27.0% to $151.1 million, while net income attributable to TPB declined 81.4% to $3.93 million. The company is expanding the US retail presence of its FRE and ALP nicotine pouch brands and expects its Modern Oral chain-store footprint to grow by more than 70% during 2026. Selling, general and administrative expenses increased 69.1% to $75.3 million, while PMTA-related expenses reached approximately $3.15 million and manufacturing start-up costs totaled about $593,000. ALP plans to open a branded pop-up in New York City's SoHo neighborhood on November 13, alongside a marketing campaign extending into January 2027. TPB owns 50% of ALP but consolidates the venture in its financial statements.
company
Nov.11